Current Perspectives on Anti-Infective Agents PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Current Perspectives on Anti-Infective Agents PDF full book. Access full book title Current Perspectives on Anti-Infective Agents by K. Tamreihao. Download full books in PDF and EPUB format.
Author: K. Tamreihao Publisher: Bentham Science Publishers ISBN: 9811432724 Category : Medical Languages : en Pages : 278
Book Description
The volume is a comprehensive documentation on major infectious diseases from tropical countries which pose a serious threat to global healthcare programs. These include diseases such as tuberculosis, AIDS, leishmaniasis (kala-azar), elephantiasis, malaria, leprosy, various fungal disorders and emergent viral diseases. Due to the widespread use of antibiotics, there is an emergence of drug-resistant pathogens in many regions. Hence, there is a need to search for novel, cost-effective bioactive compounds that demonstrate high efficacy and low toxicity in human cells from unexplored ecosystems to combat emerging drug-resistant pathogens. Chapters of this volume focus on the pathogenesis and etiology of each of the mentioned diseases, updated WHO reports wherever applicable, conventional drugs and their pharmacokinetics as well as new approaches to develop anti-infective agents. The authors also present a detailed report on ‘superbugs’ (multi-drug resistant pathogens) and new measures being taken up to eradicate them. Information about new antimicrobials (bioactive peptides and silk protein sericin) and the approaches taken by scientists and healthcare professionals for successful targeting of these molecules for human medicine. This volume is essential for general readers, healthcare professionals, researchers, and academicians actively involved in research on infectious diseases and anti-infective therapeutic drugs. [Series Introduction] Frontiers in Anti-Infective Agents is a book series that focuses on current and new antibiotics and vaccines. The series highlights the challenges faced by healthcare workers around the globe when facing epidemics caused by life-threatening pathogens along with the measures being taken to combat these challenges. The series is essential reading for all involved in infectious disease research including microbiologists, medical professionals, epidemiologists, and life science researchers.
Author: George G. Jackson Publisher: Springer ISBN: 9783642466670 Category : Medical Languages : en Pages : 478
Book Description
Pharmaceutical research has a long-standing tradition at Bayer since the establish ment of a Pharmaceutical Department 25 years after the foundation of the Farben fabriken of Friedrich Bayer & Co. in the city of Elberfeld, Germany. In 1888, one of the first antipyretic drugs, phenacetin, was synthesized. A milestone was marked by the discovery and launch of Aspirin TM in 1899, the most widely used and appreciated drug since then. The success of Bayer 205 (GermaninTM) in the treatment of sleeping sickness led not only to the worldwide recognition of Bayer as a pharmaceutical company but also to intense research into antiinfective therapy. The antimalarial drugs Atebrin TM, Plasmochin TM and Resochin TM were the first of a whole series of significant contribu tions and even breakthroughs in the therapy of infections. The advances and the success of antibacterial therapy were heralded by the discovery of the antibacterial activity of the sulfonamides by Domagk, Klarer and Mietsch. The first drug of this class of compounds, ProntosilTM, opened the new era of therapeutic control of bacterial infections. In 1939, Domagk received the Nobel Prize for Medicine for this breakthrough. A further breakthrough in the chemotherapy of the scourge of tuber culosis was achieved in 1946 by Domagk and his colleagues Behnisch, Mietzsch and Schmidt with the development of Conteben TM, followed shortly afterwards by the discovery of isoniazid (Neoteben TM) by Domagk, Offe and Siefken.
Author: Horst Dieter Schlumberger Publisher: Vieweg+teubner Verlag ISBN: Category : Medical Languages : en Pages : 316
Book Description
Pharmaceutical research has a long-standing tradition in Bayer since the estab lishment of a Pharmaceutical Department 25 years after the foundation of the Farbenfabriken of Friedrich Bayer & Co. in the city of Elberfeld, Germany. In 1888 one of the first antipyretic drugs, phenacetin, was synthesized. A mile stone was marked by the discovery and launch of Aspirin (tm) in 1899, the most widely used and appreciated drug since then. The success of Bayer 205 (Germanin TM) in the treatment of sleeping sickness 1ed not only to the worldwide recognition of Bayer as a pharmaceutical com pany but also to intense research into anti-infective therapy. The antimalarial drugs Atebrin TM, Plasmochin (tm) and Resochin (tm) were the first of a whole series of significant contributions and even breakthroughs in the therapy of infections. The advances and the success of antibacterial therapy was heralded by the discovery of the antibacterial activity of the sulfonamides by Domagk, Klarer and Mietsch. The first drug of this class of compounds, Prontosil(tm), opened the new era of therapeutic control of bacterial infections. In 1939 Domagk received the Nobel Prize for Medicine for this breakthrough. A furt her breakthrough in the chemotherapy of the scourge of tuberculosis was achieved in 1946 by Domagk and his colleagues Behnisch, Mietzsch and Schmidt with the development of Conte ben TM, followed shortly afterwards by the discovery of isoniazid (Neoteben TM) by Domagk, Offe and Siefken.
Author: Anton Ficai Publisher: Elsevier ISBN: 0323461514 Category : Science Languages : en Pages : 724
Book Description
Nanostructures for Antimicrobial Therapy discusses the pros and cons of the use of nanostructured materials in the prevention and eradication of infections, highlighting the efficient microbicidal effect of nanoparticles against antibiotic-resistant pathogens and biofilms. Conventional antibiotics are becoming ineffective towards microorganisms due to their widespread and often inappropriate use. As a result, the development of antibiotic resistance in microorganisms is increasingly being reported. New approaches are needed to confront the rising issues related to infectious diseases. The merging of biomaterials, such as chitosan, carrageenan, gelatin, poly (lactic-co-glycolic acid) with nanotechnology provides a promising platform for antimicrobial therapy as it provides a controlled way to target cells and induce the desired response without the adverse effects common to many traditional treatments. Nanoparticles represent one of the most promising therapeutic treatments to the problem caused by infectious micro-organisms resistant to traditional therapies. This volume discusses this promise in detail, and also discusses what challenges the greater use of nanoparticles might pose to medical professionals. The unique physiochemical properties of nanoparticles, combined with their growth inhibitory capacity against microbes has led to the upsurge in the research on nanoparticles as antimicrobials. The importance of bactericidal nanobiomaterials study will likely increase as development of resistant strains of bacteria against most potent antibiotics continues. Shows how nanoantibiotics can be used to more effectively treat disease Discusses the advantages and issues of a variety of different nanoantibiotics, enabling medics to select which best meets their needs Provides a cogent summary of recent developments in this field, allowing readers to quickly familiarize themselves with this topic area
Author: Mohmmad Younus Wani Publisher: Academic Press ISBN: 0128205784 Category : Business & Economics Languages : en Pages : 270
Book Description
Combination Therapy against Multidrug Resistance explores the potential of combination therapy as an efficient strategy to combat multi-drug resistance. Multidrug resistance (MDR) occurs when microorganisms such as bacteria, fungi, viruses, and parasites are excessively exposed to antimicrobial drugs such as antibiotics, antifungals, or antivirals, and in response the microorganism undergoes mutations or develops different resistance mechanisms to combat the drug for its survival. MDR is becoming an increasingly serious problem in both developed and developing nations. Bacterial resistance to antibiotics has developed faster than the production of new antibiotics, making bacterial infections increasingly difficult to treat, and the same is true for a variety of other diseases. Combination therapy proves to be a promising strategy as it offers potential benefits such as a broad spectrum of efficacy, greater potency than the drugs used in monotherapy, improved safety and tolerability, and reduction in the number of resistant organisms. This book considers how combination therapy can be applied in multiple situations, including cancer, HIV, tuberculosis, fungal infections, and more. Combination Therapy Against Multidrug Resistance gathers the most relevant information on the prospects of combination therapy as a strategy to combat multridrug resistance and helping to motivate the industrial sector and government agencies to invest more in research and development of this strategy as a weapon to tackle the multidrug resistance problem. It will be useful to academics and researchers involved in the development of new antimicrobial or antiinfective agents and treatment strtategies to combat multidrug resistance. Clinicians and medical nurses working in the field of infection prevention and control (IPC) will also find the book relevant Explores strategic methods with investigation of both short- and long-term goals to combat multidrug resistance Presents a broad scope to understand fully the ways to apply combined therapy to multidrug resistance Provides an overview of combination therapy, but also includes specific cases such as cancer, tuberculosis, HIV and malaria
Author: K. Tamreihao
Author: G.G. Jackson
Author: G. G. Jackson
Author: George Gee Jackson
Author: George G. Jackson
Author: Horst Dieter Schlumberger
Author: George Gee Jackson
Author: 
Author: Anton Ficai
Author: Mohmmad Younus Wani
Author: National Library of Medicine (U.S.)